Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer will present a corporate overview at the 24th...
-
U.S. Food and Drug Administration (FDA) Cleared Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in 2022 ...
-
NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus,...
-
NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus,...
-
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the...
-
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will...
-
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK,...
-
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific...
-
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate...
-
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announces financial results for the fourth quarter and year ended...